Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-08-23
2011-08-23
Goldberg, Jeanine A (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S091200, C435S287100, C435S007100, C435S006110, C435S006140
Reexamination Certificate
active
08003327
ABSTRACT:
A method of screening a subject for a proliferative disease risk factor comprises detecting the presence or absence of upregulation of the CLN3 gene in the subject. The upregulation of the CLN3 gene in the subject indicates the subject is at increased risk of developing a proliferative disease. Methods of screening compounds for the treatment of proliferative diseases based on the CLN3 gene and its product are also disclosed, along with methods of treating such diseases and vectors useful therefore.
REFERENCES:
patent: 4599308 (1986-07-01), Hamer et al.
patent: 4797368 (1989-01-01), Carter et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5173414 (1992-12-01), Lebkowski et al.
patent: 5176996 (1993-01-01), Hogan et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5288514 (1994-02-01), Ellman
patent: 5354678 (1994-10-01), Lebkowski et al.
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5445934 (1995-08-01), Fodor et al.
patent: 5468634 (1995-11-01), Liu
patent: 5474935 (1995-12-01), Chatterjee et al.
patent: 5518913 (1996-05-01), Massie et al.
patent: 5565324 (1996-10-01), Still et al.
patent: 5585269 (1996-12-01), Earp, III et al.
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5587308 (1996-12-01), Carter et al.
patent: 5589477 (1996-12-01), Chokai et al.
patent: 5604090 (1997-02-01), Alexander et al.
patent: 5616326 (1997-04-01), Spibey
patent: 5622856 (1997-04-01), Natsoulis
patent: 5650316 (1997-07-01), Aggarwal et al.
patent: 5658776 (1997-08-01), Flotte et al.
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5677158 (1997-10-01), Zhou et al.
patent: 5681731 (1997-10-01), Lebkowski et al.
patent: 5707865 (1998-01-01), Kohn et al.
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 5747335 (1998-05-01), Haseloff et al.
patent: 5766942 (1998-06-01), Haseloff et al.
patent: 5773260 (1998-06-01), Goldberg et al.
patent: 5811537 (1998-09-01), Griesen
patent: 5817635 (1998-10-01), Eckstein et al.
Dermer et al. (Biotechnology vol. 12, Mar. 1994, p. 320).
Chabert et al. (Int. J. Cancer: 53, 837-842 (1993)).
Altschul, et al., Basic Local Alignment Search Tool,J. Mol. Biol., vol. 215, pp. 403-410 (1990.
Amarnath, et al., Chemical Synthesis of Oligonucleotides,Chemical Reviews, vol. 77, No. 2, pp. 193-217 (1977).
Andersson, et al., Cloning, Structure, and Expression of the Mitochondrial Cytochrome P-450 Sterol 26-Hydroxylase, a Bile Acid Biosynthetic Enzyme,Journal of Biological Chemistry, vol. 264, No. 14, pp. 8222-8229 (1989).
Arends, et al., Apoptosis: The Role of the Endonuclease,American Journal of Pathology, vol. 136, No. 3, pp. 593-608).
Atherton, et al., The Solid Phase in Solid-Phase Synthesis,Perspectives in Peptide Chemistry, pp. 101-117 (Karger, Basel 1981).
Bligh, et al., A Rapid Method of Total Lipid Extraction and Purification,Canadian Journal of Biochemistry and Physiology, vol. 37, No. 8, pp. 911-917 (Aug. 1959).
Boustany, et al., Neurological Progress—The Neuronal Ceroid Lipofuscinoses:A Review, Revue Neurologique, vol. 145, No. 2, pp. 105-110 (1989).
Boustany, Rose-Mary, Neurology of the Neuronal Ceroid-Lipofuscinoses: Late Infantile and Juvenile Types,American Journal of Medical Genetics, vol. 42, pp. 533-535 (1992).
Boustany, et al., Clinical Classification of Neuronal Ceroid-Lipofuscinosis Subtypes,American Journal of Medical Genetics Supplement, vol. 5, pp. 47-58 (1988).
Fleck, et al., Modifications of the E. coli Lac repressor for expression in eukaryotic cells: effects of nuclear signal sequences on protein activity and nuclear accumulation,Nucleic Acids Research, vol. 20, No. 7, pp. 1785-1791 (Apr. 11, 1992).
Friedmann, Theodore, Progress Toward Human Gene Therapy,Science, vol. 244, pp. 1275-1281 (Jun. 16, 1989).
Fridkin, Mati, Polymeric Reagents in Peptide Synthesis,The Peptides, vol. 2, pp. 333-363 (1979).
Stoll, et al., Effect of Vincristine on Sister Chromatid Exchanges of Normal Hyman Lymphocytes,Cancer Research, vol. 36, pp. 2710-2713 (Aug. 1976).
Howard, et al., Cell Cycle Arrest of Proliferating Neuronal Cells by Serum Deprivation Can Result in Either Apoptosis or Differentiation,Journal of Neurochemistry, vol. 60, No. 5, pp. 1783-1791 (May 1993).
Kaufmann, et al., Specific Proteolytic Cleavage of Poly(ADP-ribose) Polymerase: An Early Marker of Chemotherapy-induced Apoptosis,Cancer Research, pp. 3976-3985 (Sep. 1, 1993).
Obeid, et al., Programmed Cell Death Induced by Ceramide,Science, vol. 259, pp. 1769-1771 (Mar. 19, 1993).
Perry, et al., Bcl-2 acts upstream of the PARP protease and prevents it activation,Cell Death and Differentiation, vol. 4; No. 1, pp. 29-33 (1997).
Rosenbaum, et al., Evidence of Hypoxia-induced, Programmed Cell Death of Cultured Neurons,Annals of Neurology, vol. 36, No. 6, pp. 864-870).
Walker, P. Roy, et al., Topoisomerase II-reactive Chemotherapeutic Drugs Induce Apoptosis in Thymocytes,Cancer Research, vol. 51, No. 4, pp. 1078-1085 (Feb. 15, 1991).
Woo, Savio L.C., Adenovirus redirected,Nature Biotechology, vol. 14, No. 11, p. 1538 (Nov. 1996).
Lee, et al., Ceramide Inactivates Cellular Protein Kinase Cα,Journal of Biological Chemistry, vol. 271, No. 22, pp. 13169-13174 (May 31, 1996).
Zhang, et al., Bc1-2 interrupts the ceramide-mediated pathway of cell death,Proc. Natl. Acad. Sci. USA, vol. 93, pp. 5325-5328 (May 1996).
Bertrand, et al., Induction of a Common Pathway of Apoptosis by Staurosporine,Experimental Cell Research, vol. 211, pp. 314-321 (1994).
Boustany, R-M, et al., Seizures, Depression and Dementia in Teenagers with Batten Disease,J. Inher. Metab. Dis., vol. 16, pp. 252-255 (1993).
Griffith, et al., Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege,Science, vol. 270, pp. 1189-1193 (Nov. 17, 1995).
Griffith, et al., CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance,Immunity, vol. 5, pp. 7-16 (Jul. 1996).
Hannun, Yusuf A., Functions of Ceramide in Coordinating Cellular Responses to Stress,Science, vol. 274, pp. 1855-1859 (Dec. 13, 1996).
Janes, et al, A model of Batten disease protein CLN3: Functional implications from homology and mutations,Federation of European Biochemical Societies, vol. 399, pp. 75-77 (1996).
Kulkarni, et al,. Serum deprivation induces apoptotic cell death in a subset of Balb/c 3T3 fibroblasts,Journal of Cell Science, vol. 107, pp. 1169-1179 (1994).
Lane, et al., Apoptosis as the Mechanism of Neurodegeneration in Batten's Disease,Journal of Neurochemistry, vol. 67, No. 2, pp. 677-683 (1996).
Liu, et al., Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c,Cell, vol. 86, pp. 147-157 (Jul. 12, 1996).
Mitchison, et al., Genomic Structure and Complete Nucleotide Sequence of the Batten Disease, Gene, CLN3,Genomics, vol. 40, pp. 346-350 (1997).
Pena, et al., Stress-Induced Apoptosis and the Sphingomyelin Pathway,Biochemical Pharmacology, vol, 53, pp. 615-621 (1997).
Puranam, et al., Upregulation of Bcl-2 and Elevation of Ceramide in Batten Disease,Neuropediatrics, vol. 28, pp. 37-41 (1997).
Smyth, et al., prICE: a downstream target for ceramide-induced apoptosis and for the inhibitory action of Bcl-2,Biochem. J., vol. 316, pp. 25-28 (1996).
The International Batten Disease Consortium, Isolation of a Novel Gene Underlying Batten Disease, CLN3,Cell, vol. 82, pp. 949-957 (Sep. 22, 1995).
White, Eileen, Life, death, and the pursuit of apoptosis,Genes&Development, vol. 10, pp. 1-15 (1996).
Chabert et al. “Cell Culture of Tumors Alters Endogenous Poly (ADPR) Polymerase Expression and Activity”Int. J. Cancer53:837-842 (1993).
Dermer. “Another Anniversary for the War on Cancer”Bio/Technology12:320 (1994).
Persaud-Sawin et al. “Motifs Within the CLN3 Protein: Modulation of Cell Growth Rates and Apoptosis”Human Molecular Genetics11(18):2129-2142 (2002).
Rylova et al. “TheCLN3Gene is a Novel Molecular Target for Cancer Drug Discovery”Cancer Research62:801-808 (2002).
Amalfitano Andrea
Boustany Rose-Mary N.
Guo Wei-Xing
Duke University
Goldberg Jeanine A
Myers Bigel Sibley & Sajovec P.A.
LandOfFree
Methods of screening for risk of proliferative disease and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of screening for risk of proliferative disease and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of screening for risk of proliferative disease and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2686398